Fosamax and Osteonecrosis of the Jaw: Understanding the Pathophysiology and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Occupational Exposure Concerns

The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and therapeutic interventions. Within this broad framework, discussions of bone health and pharmaceutical treatments have been standard topics, emphasizing the balance between benefits and potential adverse effects. This heritage provides a necessary backdrop for examining more specialized concerns that arise when therapeutic agents are used in specific populations or settings. Transitioning from this general health perspective, attention now turns to occupational exposure scenarios where individuals may encounter pharmaceutical compounds in their work environment. The focus narrows to bisphosphonate medications, particularly those containing alendronate, which are commonly prescribed for osteoporosis management. In occupational settings, workers involved in manufacturing, handling, or administering these drugs may face unique exposure considerations that differ from typical patient use. This shift from broad health education to occupational exposure concern highlights the importance of understanding how workplace contact with pharmaceutical agents might influence health outcomes. The discussion moves beyond general therapeutic contexts to consider the implications of repeated or concentrated exposure in professional environments, setting the stage for examining specific risk factors associated with such occupational scenarios.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the occupational exposure framework, this section transitions to the specific pharmaceutical agent Fosamax (alendronate) and its association with osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption, which increases bone mass and reduces fracture risk. However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section establishes the clinical context and introduces the mechanistic pathways that will be explored in detail.

Pathophysiology: How Fosamax Triggers Osteonecrosis of the Jaw

The pathophysiology linking Fosamax to ONJ involves several mechanistic pathways. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw. They inhibit osteoclast activity, which reduces bone remodeling. This suppression of normal bone turnover can impair the jawbone's ability to repair microdamage and respond to local stressors, such as dental procedures or infection. The jawbone's unique structure and function may make it especially vulnerable to these effects. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Research using estrogen-deficient rat models has examined the effects of bisphosphonate (alendronate) treatment on jawbone properties, including tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077/). These studies contribute to understanding how bisphosphonates alter jawbone physiology in ways that may predispose to ONJ.

Clinical Presentation, Risk Factors, and Diagnosis

The clinical presentation of ONJ typically involves exposed bone in the jaw that persists for more than eight weeks. Diagnosis is based on clinical examination and imaging, and it requires ruling out other causes such as metastatic disease or osteoradionecrosis. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning about osteonecrosis of the jaw. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also indicates that in placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized risk, its incidence in clinical trials was low and not statistically different from placebo, which may affect how patients and clinicians perceive the risk.

Causation Considerations and Timeline

Causation considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship in some cases. However, ONJ can also occur spontaneously or due to other risk factors, making it challenging to attribute causation solely to Fosamax in individual cases. The presence of known risk factors, such as dental procedures or cancer therapy, may confound the association. The timeline between exposure and documented harm can vary widely. Onset of symptoms has been reported from as early as one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, management typically involves discontinuation of the bisphosphonate, conservative debridement, and antibiotic therapy. The label advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients at low risk for fracture, the label also suggests considering drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may reduce the risk of ONJ.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) accumulates in bone, especially in high-turnover areas like the jaw, and inhibits osteoclast activity, reducing bone remodeling. This impairs the jawbone's ability to repair microdamage and respond to stressors, leading to ONJ. Research using animal models has shown altered jawbone properties (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and comorbidities like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Longer duration of bisphosphonate use also increases risk.

How long after starting Fosamax can ONJ develop?

Onset of symptoms has been reported from as early as one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.